Remove Assay Development Remove Disease Remove Drug Research
article thumbnail

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

Sygnature Discovery

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The biotech will continue partnering with Sygnature to drive its novel, genetically validated cardiovascular disease project pipeline.